Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Health-System Pharmacy, Vol. 63, Number 18 Supplement 4, S19-S41
Copyright © 2006 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pucino, F.
Right arrow Articles by Goldbach-Mansky, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pucino, F., Jr.
Right arrow Articles by Goldbach-Mansky, R.

Use of biologics in rheumatoid arthritis: Where are we going?

Frank Pucino, Jr., Phyllis Tish Harbus and Raphaela Goldbach-Mansky

FRANK PUCINO, JR., PHARM.D., BCPS, FDPGEC, FASHP, is Ambulatory Care Clinical Pharmacy Team Leader, Clinical Adjunct Associate Professor, Howard University College of Pharmacy, Washington, DC. PHYLLIS TISH HARBUS is Medical Writer, Editor, Editorial Consultant, New York, NY. RAPHAELA GOLDBACH-MANSKY, M.D., MHS, is Clinical Investigator, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD.

Address correspondence to Dr. Pucino at 2300 4th Street NW, Washington, DC 20059 (fpucinojr{at}yahoo.com).


Purpose. The pharmacology, efficacy, safety, and costs of biologic agents that are approved by the Food and Drug Administration or are under review for the management of rheumatoid arthritis (RA) are discussed. Biologic therapies that are currently under investigation in early- and late-phase clinical trials are summarized at the end of this report.

Summary. The use of biologic agents for the treatment of RA has significantly improved the management of this disease. Experimental and clinical studies have shown that these agents ameliorate the signs and symptoms of RA, slow radiographic progression of disease, and improve physical function and quality of life. Data also support that early initiation of therapy with these agents improves long-term outcomes. However, biologic agents are associated with adverse effects that health care providers need to recognize and manage.

Conclusion. Biologic agents have revolutionized the treatment of RA by reducing the signs and symptoms of RA, slowing radiographic progression of joint destruction, and improving physical function and quality of life in affected patients.

Index terms: Arthritis; Biologicals; Costs; Quality of life; Toxicity

 



This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
A. Sebba
Tocilizumab: The first interleukin-6-receptor inhibitor
Am. J. Health Syst. Pharm., August 1, 2008; 65(15): 1413 - 1418.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
A. K Rowley, B. H Resman-Targoff, C. A Marra, and F. Pucino
Evolution of Clinical Pharmacy in the Practice of Rheumatology
Ann. Pharmacother., October 1, 2007; 41(10): 1705 - 1707.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Health-System Pharmacists.